Enesi Pharma, a pharmaceutical company developing unique injectable solid dose vaccine products, has appointed James Cheyne to its Scientific Advisory Board (SAB).
Enesi’s SAB comprises experts in vaccines and preventative health from leading academic, research and international health organisations across the US and Europe.
Cheyne is an acknowledged expert in the key area of vaccine delivery, with experience working in leadership, senior advisory and consultancy roles at international health organisations including the World Health Organization (WHO), PATH, the Bill & Melinda Gates Foundation, GAVI The Vaccine Alliance and UNICEF.
Cheyne was cofounder of the Cold Chain Unit at the WHO, which for more than 20 years developed vaccine cold chain policies and practices still widely used in many countries today. The unit also brought auto-disable syringes, vaccine vial monitors and ice-lined refrigerators to market.
Cheyne has also advised Government Ministries in more than 50 countries around the world to ensure and improve the effectiveness of vaccine logistics.
He joins existing SAB members Professor Jeffrey Almond, Professor Christopher J. Davis OBE, Dr Philip Minor and Karl Simpson.
David Hipkiss, CEO of Enesi Pharma, said: “Enesi is delighted to welcome James to the SAB and we are thrilled to have made such a high-quality appointment. He brings unique insight to the challenges faced by international health organisations in tackling global health issues and delivering effective vaccination programmes both in low and middle income countries. His experience and knowledge will surely prove invaluable as the company advances the development of its novel solid-dose vaccine products and business in the coming years.”
Cheyne added: “There still remain significant challenges to providing vaccination to populations where it is needed despite the incredible efforts and commitment of health organisations around the world. Innovation is crucial, and I am pleased to provide my first-hand experience and insight to companies, such as Enesi Pharma, which are focused on addressing these challenges with new technologies and products.”
